{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T10:55:22Z","timestamp":1759056922865},"reference-count":38,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2012,2,20]],"date-time":"2012-02-20T00:00:00Z","timestamp":1329696000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0031784","type":"journal-article","created":{"date-parts":[[2012,2,20]],"date-time":"2012-02-20T22:13:49Z","timestamp":1329776029000},"page":"e31784","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":19,"title":["Lymphocyte Subsets Show Different Response Patterns to In Vivo Bound Natalizumab\u2014A Flow Cytometric Study on Patients with Multiple Sclerosis"],"prefix":"10.1371","volume":"7","author":[{"given":"Andrea","family":"Harrer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Pilz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Max","family":"Einhaeupl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Oppermann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfgang","family":"Hitzl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Wipfler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johann","family":"Sellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Golaszewski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Afazel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabeth","family":"Haschke-Becher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eugen","family":"Trinka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joerg","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2012,2,20]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.drudis.2006.06.008","article-title":"The impact of interferon-beta treatment on the blood-brain barrier.","volume":"11","author":"J Kraus","year":"2006","journal-title":"Drug Discov Today"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1056\/NEJMe020157","article-title":"Alpha4 integrins as therapeutic targets in autoimmune disease.","volume":"348","author":"UH von Andrian","year":"2003","journal-title":"N Engl J Med"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jneuroim.2004.09.005","article-title":"Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS.","volume":"158","author":"MJ Eikelenboom","year":"2005","journal-title":"J Neuroimmunol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/1352458510383075","article-title":"Adhesion molecules are promising candidates to establish surrogate markers for natalizumab treatment.","volume":"17","author":"P Wipfler","year":"2011","journal-title":"Mult Scler"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/356063a0","article-title":"Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin.","volume":"356","author":"TA Yednock","year":"1992","journal-title":"Nature"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jns.2008.05.021","article-title":"Antigen-specific therapies in MS - Current concepts and novel approaches.","volume":"274","author":"A Lutterotti","year":"2008","journal-title":"J Neurol Sci"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.drudis.2010.10.011","article-title":"Recent developments in approved and oral multiple sclerosis treatment and an update on future treatment options.","volume":"16","author":"P Wipfler","year":"2011","journal-title":"Drug Discov Today"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1056\/NEJMoa044397","article-title":"A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"354","author":"CH Polman","year":"2006","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJMoa020696","article-title":"A controlled trial of natalizumab for relapsing multiple sclerosis.","volume":"348","author":"DH Miller","year":"2003","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1212\/01.wnl.0000327671.91357.96","article-title":"Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis.","volume":"71","author":"M Krumbholz","year":"2008","journal-title":"Neurology"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jneuroim.2011.02.010","article-title":"Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients.","volume":"235","author":"M Skarica","year":"2011","journal-title":"J Neuroimmunol"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.jneuroim.2010.07.012","article-title":"Natalizumab treatment reduces endothelial activity in MS patients.","volume":"227","author":"A Millonig","year":"2010","journal-title":"J Neuroimmunol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1001\/archneur.62.10.1620","article-title":"Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.","volume":"62","author":"O Stuve","year":"2005","journal-title":"Arch Neurol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1001\/archneur.65.12.noc80051","article-title":"Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.","volume":"65","author":"MM del Pilar","year":"2008","journal-title":"Arch Neurol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJM198802043180507","article-title":"Involvement of JC virus-infected mononuclear cells from the bone marrow and spleen in the pathogenesis of progressive multifocal leukoencephalopathy.","volume":"318","author":"SA Houff","year":"1988","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"3893","DOI":"10.1182\/blood-2007-10-120329","article-title":"The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans.","volume":"111","author":"F Zohren","year":"2008","journal-title":"Blood"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S1474-4422(10)70028-4","article-title":"Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.","volume":"9","author":"DB Clifford","year":"2010","journal-title":"Lancet Neurol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1212\/01.wnl.0000277457.17420.b5","article-title":"The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL.","volume":"69","author":"PA Calabresi","year":"2007","journal-title":"Neurology"},{"key":"ref19","article-title":"Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab.","author":"PS Sorensen","year":"2011","journal-title":"Mult Scler"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \u201cMcDonald Criteria\u201d.","volume":"58","author":"CH Polman","year":"2005","journal-title":"Ann Neurol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1600-0404.1998.tb01727.x","article-title":"Soluble and cell surface ICAM-1 as markers for disease activity in multiple sclerosis.","volume":"98","author":"J Kraus","year":"1998","journal-title":"Acta Neurol Scand"},{"key":"ref22","first-page":"548","article-title":"Soluble and cell surface bound adhesion molecules in blood and cerebrospinal fluid as diagnostic markers and parameters for disease activity, disease severity and treatment efficacy in patients with multiple sclerosis.","volume":"25","author":"J Kraus","year":"2001","journal-title":"J Lab Med"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jneuroim.2011.03.001","article-title":"Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells.","volume":"234","author":"A Harrer","year":"2011","journal-title":"J Neuroimmunol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1002\/ana.20859","article-title":"Natalizumab effects on immune cell responses in multiple sclerosis.","volume":"59","author":"M Niino","year":"2006","journal-title":"Ann Neurol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.4049\/jimmunol.173.3.1663","article-title":"IFN-alpha subtypes differentially affect human T cell motility.","volume":"173","author":"GR Foster","year":"2004","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1001\/archneur.63.10.1383","article-title":"Altered CD4+\/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.","volume":"63","author":"O Stuve","year":"2006","journal-title":"Arch Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1046\/j.1365-2249.2002.01711.x","article-title":"Differential expression of beta1 and beta2 integrins and L-selectin on CD4+ and CD8+ T lymphocytes in human blood: comparative analysis between isolated cells, whole blood samples and cryopreserved preparations.","volume":"127","author":"M Cavers","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0165-5728(98)00014-9","article-title":"A role for natural killer cells in the immunopathogenesis of multiple sclerosis.","volume":"86","author":"LF Kastrukoff","year":"1998","journal-title":"J Neuroimmunol"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jneuroim.2003.10.001","article-title":"Clinical relapses of multiple sclerosis are associated with \u2018novel\u2019 valleys in natural killer cell functional activity.","volume":"145","author":"LF Kastrukoff","year":"2003","journal-title":"J Neuroimmunol"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.1182\/blood.V97.10.3146","article-title":"Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset.","volume":"97","author":"MA Cooper","year":"2001","journal-title":"Blood"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/j.1365-2249.2007.03555.x","article-title":"Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells.","volume":"151","author":"L Airas","year":"2008","journal-title":"Clin Exp Immunol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10072-007-0803-3","article-title":"Expansion of CD56Bright natural killer cells in the peripheral blood of multiple sclerosis patients treated with interferon-beta.","volume":"28","author":"M Saraste","year":"2007","journal-title":"Neurol Sci"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"5941","DOI":"10.1073\/pnas.0601335103","article-title":"Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.","volume":"103","author":"B Bielekova","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1212\/WNL.52.5.1072","article-title":"A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.","volume":"52","author":"WA Sheremata","year":"1999","journal-title":"Neurology"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"15","DOI":"10.2174\/138920006774832604","article-title":"Early development of therapeutic biologics\u2013pharmacokinetics.","volume":"7","author":"A Baumann","year":"2006","journal-title":"Curr Drug Metab"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/nri2155","article-title":"FcRn: the neonatal Fc receptor comes of age.","volume":"7","author":"DC Roopenian","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ab.2011.01.001","article-title":"Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody.","volume":"411","author":"T Rispens","year":"2011","journal-title":"Anal Biochem"},{"key":"ref38","article-title":"CD49d expression as a promising biomarker to monitor natalizumab efficacy.","author":"G Defer","year":"2011","journal-title":"J Neurol Sci"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0031784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,10,23]],"date-time":"2018-10-23T09:47:22Z","timestamp":1540288042000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0031784"}},"subtitle":[],"editor":[{"given":"Pablo","family":"Villoslada","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2012,2,20]]},"references-count":38,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2012,2,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0031784","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,20]]}}}